Tralokinumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis in Patients Aged 12 years and Older With and Without Atopic Comorbidities. J of Skin. 2024;8(1):s322. doi:10.25251/skin.8.supp.322